publications-banner

Information about pipeline products

PublicationView

T-DXd
Gastric Cancer
Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer: A plain language summary of the DESTINY-Gastric01 study
Shitara K.
Future Oncol. 2024;20(2):59-70.
Dato-DXd
Lung Cancer Other/Multi
Application of the model-informed drug development paradigm to datopotamab deruxtecan dose selection for late-stage development
Lu Y, Liang S, Hong Y, et al.
CPT Pharmacometrics Syst Pharmacol. 2024;13(1):23-28.
Edoxaban
Cardiovascular - AF
Echocardiographic parameters of left atrial structure and function and clinical outcomes at 2 years in elderly patients with atrial fibrillation — The ANAFIE echocardiographic substudy
Hiasa K-I, Kaku H, Inoue H, et al.
Circ J. 2024;88(7):1155-1164.
Edoxaban
Cardiovascular - AF
Impact of cognitive impairment on clinical outcomes in elderly patients with atrial fibrillation: ANAFIE registry
Nagata K, Inoue H, Yamashita T, et al.
BMJ Neurol Open. 2023;5:e000370.
T-DXd
Other/Multi
Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: Primary results from the DESTINY-PanTumor02 phase II trial
Meric-Bernstam F, Makker V, Oaknin A, et al.
J Clin Oncol. 2024;42(1):47-58.
T-DXd
Breast Cancer
Analytical and clinical validation of PATHWAY Anti-HER-2/neu (4B5) antibody to assess HER2-low status for trastuzumab deruxtecan treatment in breast cancer
Garrido C, Manoogian M, Ghambire D, et al.
Virchows Arch. 2023. doi: 10.1007/s00428-023-03671-x. Online ahead of print.
Edoxaban
Cardiovascular - AF
Direct oral anticoagulant dosing in patients with atrial fibrillation: An Asian perspective
Chao T-F, Chan N-Y, Chan Y-H, et al.
JACC: Asia. 2023;3(5):707-723.
T-DXd
Breast Cancer
Treatment with trastuzumab deruxtecan in patients with HER2-positive breast cancer and brain metastases and/or leptomeningeal disease (ROSET-BM)
Niikura N, Yamanaka T, Nomura H, et al.
NPJ Breast Cancer. 2023;9(1):82.
Pexidartinib
Other/Multi
Supporting patients in the transition to the revised pexidartinib dosing regimen: Perspectives from the multidisciplinary clinical and allied health professional team
McCabe C, Wright H, Polson K, Wagner AJ.
Orphanet J Rare Dis. 2023;18(1):313.
HER3-DXd
Breast Cancer
Patritumab deruxtecan (HER3-DXd), a human epidermal growth factor receptor 3-directed antibody-drug conjugate, in patients with previously treated human epidermal growth factor receptor 3-expressing metastatic breast cancer: A multicenter, phase I/II trial
Krop IE, Masuda N, Mukohara T, et al.
J Clin Oncol. 2023;41(36):5550-5560.
Pages: 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  

footer